Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 221 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Celecoxib Clear all
Completed Phase 2 Interventional

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

NCT00068432
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Celecoxib, Gemcitabine Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
11
States / cities
Fort Smith, Arkansas • Orlando, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.

NCT04526197
View directory record Official record
Conditions
Wilson Disease
Interventions
ALXN1840, Celecoxib
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Toradol v. Celecoxib for Postoperative Pain

NCT03331315
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Celecoxib, Ketorolac
Drug
Lead sponsor
Michael Ulm, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject

NCT05436678
View directory record Official record
Conditions
Pharmacokinetics
Interventions
PrimeC 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg
Drug
Lead sponsor
NeuroSense Therapeutics Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 2 Interventional

Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

NCT00047281
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
celecoxib, cyclophosphamide, etoposide, thalidomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 1 Interventional

Ciprofloxacin/Celecoxib Combination in Patients With ALS

NCT04090684
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Fixed dose combination Ciprofloxacin/Celecoxib
Drug
Lead sponsor
NeuroSense Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 2 Interventional

Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer

NCT00062101
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, celecoxib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery

NCT01158534
View directory record Official record
Conditions
Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
celecoxib, recombinant interferon alfa-2b, polymerase chain reaction, laboratory biomarker analysis, reverse transcriptase-polymerase chain reaction, immunologic technique, immunohistochemistry staining method, flow cytometry
Drug · Biological · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 4, 2026, 4:54 AM EDT
Not listed Phase 1 Interventional

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120636
View directory record Official record
Conditions
Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Celecoxib
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Celecoxib as a Chemopreventive Agent in Current and Former Smokers

NCT00981201
View directory record Official record
Conditions
Smoking, Prevention
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 74 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 4, 2026, 4:54 AM EDT
Terminated Phase 2 Interventional Results available

Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)

NCT00198081
View directory record Official record
Conditions
Pancreas Neoplasms
Interventions
COX-2 Inhibitor 6-8 weeks prior to surgery, COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat

NCT00402987
View directory record Official record
Conditions
Pharyngitis
Interventions
celecoxib, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 18 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

NCT00664560
View directory record Official record
Conditions
Osteoarthritis
Interventions
PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid
Drug
Lead sponsor
POZEN
Industry
Eligibility
50 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 4, 2026, 4:54 AM EDT
Terminated Not applicable Interventional

Celecoxib in Treating Patients With Early-Stage Rectal Cancer

NCT00608595
View directory record Official record
Conditions
Colorectal Cancer
Interventions
celecoxib, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, biopsy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 4, 2026, 4:54 AM EDT
Withdrawn Phase 1 Interventional

Celecoxib Treatment for Lung Cancer

NCT00108186
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Celecoxib
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Sep 4, 2026, 4:54 AM EDT
Terminated Phase 3 Interventional

Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer

NCT00087256
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Celecoxib, placebo
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Sep 4, 2026, 4:54 AM EDT
Recruiting Phase 2 Interventional

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

NCT07174570
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Celecoxib, Durvalumab, Tremelimumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Biopsy Procedure
Drug · Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 4, 2026, 4:54 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses

NCT00027976
View directory record Official record
Conditions
Precancerous Condition
Interventions
celecoxib, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
7
States / cities
Birmingham, Alabama • Irvine, California • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2013 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.

NCT00101686
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Modified Bolus 5-FU/LV with Irinotecan, FOLFIRI + bevacizumab, miFL + bevacizumab, Infusional 5-FU/LV with Irinotecan, Oral Capecitabine with Irinotecan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
141
States / cities
Birmgingham, Alabama • Birmingham, Alabama • Birmngham, Alabama + 123 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Sep 4, 2026, 4:54 AM EDT
Terminated Phase 1 Interventional

Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

NCT01313429
View directory record Official record
Conditions
Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancies
Interventions
Cyclophosphamide, Allogenic tumor Cell Vaccine (K562), Celecoxib
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00073866
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib, docetaxel, irinotecan hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois • Joliet, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 2Phase 3 Interventional

Celecoxib in Treating Patients With Bladder Cancer

NCT00006124
View directory record Official record
Conditions
Recurrent Bladder Cancer
Interventions
celecoxib, placebo
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population

NCT00137033
View directory record Official record
Conditions
Peptic Ulcers
Interventions
Celecoxib, Naproxen, ASA
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
605 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
23
States / cities
Anaheim, California • San Diego, California • Farmington, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 4, 2026, 4:54 AM EDT
Completed Phase 2 Interventional

Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

NCT00058006
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
celecoxib, adjuvant therapy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
4
States / cities
Chicago, Illinois • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 4, 2026, 4:54 AM EDT